Surviving sepsis campaign: A critical reappraisal

Shock

Volumn 30, Issue SUPPL. 1, 2008, Pages 70-72

  Salluh, Jorge I F ^a,b   Bozza, Patrícia T ^b   Bozza, Fernando A ^c  

^a INSTITUTO NACIONAL DE CÂNCER   (Brazil)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

^c Funda??o Oswaldo Cruz   (Brazil)

Author keywords

Guidelines; Multiorgan failure; Sepsis; Severe infections; Surviving sepsis campaign

Indexed keywords

RECOMBINANT TISSUE FACTOR PATHWAY INHIBITOR;

CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; HEALTH PROGRAM; HOSPITALIZATION; HUMAN; INTENSIVE CARE UNIT; MEDICAL SOCIETY; MORTALITY; PATIENT CARE; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL; SEPSIS;

CLINICAL TRIALS AS TOPIC; HUMANS; MULTIPLE ORGAN FAILURE; PRACTICE GUIDELINES AS TOPIC; PUBLIC HEALTH; SEPSIS; SPAIN; TREATMENT OUTCOME;

EID: 54049108090     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/SHK.0b013e318181ad60     Document Type: Conference Paper

References (35)

1. Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, Gea-Banacloche J, Keh D, Marshall JC, Parker MM, et al.: Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 32(3):858-873, 2004.
2. Landucci D: The surviving sepsis guidelines: "lost in translation". Crit Care Med 32(7):1598-1600, 2004.
3. DePriest JL: Stress ulcer prophylaxis. Crir Care Med 32(7):1626, 2004.
4. Singer M: The Surviving Sepsis guidelines: evidence-based ... or evidence-biased? Crit Care Resusc 8(3):244-245, 2006.
5. Fletcher SJ, Quinn AC: The surviving sepsis campaign and sepsis care bundles: substance or sophistry? Anaesthesia 61(4):313-315, 2006.
6. Salluh JIF, Bozza FA, Soares M, Terzi RG: Brás Cubas Sepsis and the Evidence: reflections on the Surviving Sepsis Campaign. Rev Bras Ter Intens 18(4):328-331, 2006.
7. Eichacker PQ, Natanson C, Danner RL: Surviving sepsis - practice guidelines, marketing campaigns, and Eli Lilly. N Engl J Med 355(16):1640-1642, 2006.
8. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, Reinhart K, Angus DC, Brun-Buisson C, Beale R, et al.: Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 36(1):296-327, 2008.
9. Salluh JI, Soares M: New recommendations for the use of corticosteroids in sepsis: not so fast! Crit Care Med 1:1-2, 2008.
10. Schultz MJ, de Graaff MJ, Kuiper MA, Spronk PE: The new Surviving Sepsis Campaign recommendations on glucose control should be reconsidered. Intensive Care Med 34:779-780, 2008.
11. Simchen E, Sprung C, Galai N, Zitser-Gurevich Y, Bar-Lavi Y, Levi L, Zveibil F, Mandel M, Mnatzaganian G, Goldschmidt N, et al.: Survival of critically ill patients hospitalized in and out of intensive care. Crit Care Med 35(2):449-457, 2007.
12. Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, Suppes R, Feinstein D, Zanotti S, Taiberg L, et al.: Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 34(6):1589-1596, 2006.
13. Pronovost P, Needham D, Berenholtz S, Sinopoli D, Chu H, Cosgrove S, Sexton B, Hyzy R, Welsh R, Roth G, et al.: An intervention to decrease catheter-related bloodstream infections in the ICU. N Engl J Med 355(26): 2725-2732, 2006.
14. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, et al.: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344(10):699-709, 2001.
15. Annane D, Sebille V, Charpentier C, Bollaert PE, Francois B, Korach JM, Capellier G, Cohen Y, Azoulay E, Troche G, et al.: Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 288(7):862-871, 2002.
16. Van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, Bouillon R: Intensive insulin therapy in the critically ill patients. N Engl J Med 345(19):1359-1367, 2001.
17. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. N Engl J Med 342(18): 1301-1308, 2000.
18. Montori VM, Devereaux PJ, Adhikari NK, Burns KE, Eggert CH, Briel M, Lacchetti C, Leung TW, Darling E, Bryant DM, et al.: Randomized trials stopped early for benefit: a systematic review. JAMA 294(17):2203-2209, 2005.
19. Pocock SJ: When (not) to stop a clinical trial for benefit. JAMA 294(17): 2228-2230, 2005.
20. Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I, Chalupa P, Atherstone A, Pénzes I, Kübler A, et al.: Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 286(15):1869-1878, 2001.
21. The French National Registry of HA-1A (Centoxin) in Septic Shock. A cohort study of 600 patients. The National Committee for the Evaluation of Centoxin. Arch Intern Med 154(21):2484-2491, 1994.
22. Abraham E, Reinhart K, Opal S, Demeyer I, Doig C, Rodriguez AL, Beale R, Svoboda P, Laterre PF, Simon S, et al.: Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA 290(2):238-247, 2003.
23. Bertolini G, Rossi C, Anghileri A, Livigni S, Addis A, Poole D: Use of drotrecogin alfa (activated) in Italian intensive care units: the results of a nationwide survey. Intensive Care Med 33(3):426-434, 2007.
24. Nadel S, Goldstein B, Williams MD, Dalton H, Peters M, Macias WL, Abd-Allah SA, Levy H, Angle R, Wang D, et al.: Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial. Lancet 369(9564):836-843, 2007.
25. Abraham E, Laterre PF, Garg R, Levy H, Talwar D, Trzaskoma BL, Francois B, Guy JS, Bruckmann M, Rea-Neto A: Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 353(13):1332-1341, 2005.
26. Vlahakes GJ: The value of phase 4 clinical testing. N Engl J Med 354(4): 413-415, 2006.
27. Brunkhorst FM, Engel C, Bloos F, Meier-Hellmann A, Ragaller M, Weiler N, Moerer O, Gruendling M, Oppert M, Grond S, et al.: Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 358(2):125-139, 2008.
28. Vanhorebeek I, Langouche L, Van den Berghe G: Intensive insulin therapy in the intensive care unit: update on clinical impact and mechanisms of action. Endocr Pract 12(suppl 3):14-22, 2006.
29. Van den Berghe G, Wilmer A, Hermans G, Meersseman W, Wouters PJ, Milants I, Van Wijngaerden E, Bobbaers H, Bouillon R: Intensive insulin therapy in the medical ICU. N Engl J Med 354(5)449-461, 2006.
30. Sprung CL, Annane D, Keh D, Moreno R, Singer M, Freivogel K, Weiss YG, Benbenishty J, Kalenka A, Forst H, et al.: Hydrocortisone therapy for patients with septic shock. N Engl J Med 358(2):111-124, 2008.
31. Lin SM, Huang CD, Lin HC, Liu CY, Wang CH, Kuo HP: A modified goal-directed protocol improves clinical outcomes in intensive care unit patients with septic shock: a randomized controlled trial. Shock 26(6):551-557, 2006.
32. Remick DG, Ward PA: Evaluation of endotoxin models for the study of sepsis. Shock 24(suppl 1):7-11, 2005.
33. Bozza FA, Bozza PT, Castro Faria Neto HC: Beyond sepsis pathophysiology with cytokines: what is their value as biomarkers for disease severity? Mem Inst Oswaldo Cruz 100(suppl 1):217-221, 2005.
34. Bozza FA, Gomes RN, Japiassu AM, Soares M, Castro-Faria-Neto HC, Bozza PT, Bozza MT: Macrophage migration inhibitory factor levels correlate with fatal outcome in sepsis. Shock 22(4):309-313, 2004.
35. Bozza FA, Salluh JI, Japiassu AM, Soares M, Assis EF, Gomes RN, Bozza MT, Castro-Faria-Neto HC, Bozza PT: Cytokine profiles as markers of disease severity in sepsis: a multiplex analysis. Crit Care 11(2):R49, 2007.